Loading
GigaMune
GigaMune is a San Francisco company building viral carriers that turn a patient's own T cells into cancer-fighting cells inside the body, designed so that the treatment can be given more than once. NCI funds its work on melanoma.
Also called: GigaMune, Inc.GIGAMUNE, INC.
Overview
GigaMune, Inc., of San Francisco, develops in vivo CAR-T therapies and says it holds hundreds of unrelated pseudotypes, viral vectors with different envelope proteins, so that repeat doses are not blocked by immunity to the first vector. The website cites its patent US 12,371,689 B2 and shows preclinical mouse data. In fiscal year 2026 NCI awarded it USD 1,000,000 under SBIR grant 4R44CA310160-02 for a lentivector to deliver T cell receptors in vivo as a cell therapy for stage IV melanoma.
Headquarters
San Francisco, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase II (R44) award 4R44CA310160-02: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- Founding year and named programmes not stated on the website. Read on gigamune.com and NIH RePORTER on 4 November 2026.
Connected
4Similar pages
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
gigamune.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/